Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

Inclusion Criteria: * Histologically confirmed hematologic malignancy meeting 1 of the following criteria: * High-risk acute myeloid leukemia meeting 1 the following criteria: * First complete response (CR) and ≥ 60 years of age OR \< 60 years of age with high-risk cytogenetics as defined by CALGB OR high-molecular risk and not eligible or willing to undergo myeloablative conditioning * Second or later complete remission * Not in remission but with \< 5% blasts within 3 weeks of start of conditioning chemotherapy for allogeneic transplantation * Patients with a history of CNS involvement allowed provided disease is in remission at the time of transplantation * Patients with non-Hodgkin lymphoma who are candidates for allogeneic stem cell transplantation will be eligible; patients who have relapsed status post autologous transplantation are eligible as long as they demonstrate chemotherapy sensitive disease; patients with a history of CNS involvement are eligible if this aspect of the disease is in remission at the time of transplantation * High-risk chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or primary and secondary B-prolymphocytic leukemia (PLL) meeting 1 of the following criteria: * del(17p13.1) disease that has been treated (may have been given as consolidation therapy) * Less than PR to chemoimmunotherapy or relapsed within 2 years of treatment * Nucleoside analog refractory disease or disease that relapsed after two prior regimens * Patients with Richter (large cell) transformation allowed provided the large cell component of the disease is in remission (\< 10% large cells in the bone marrow allowed) * Patient has undergone an allogeneic stem cell transplantation using a reduced-intensity or non-myeloablative conditioning regimen within the past 60 days * At least 40% T-cell donor chimerism at day 30 * ECOG performance status 0-2 (Karnofsky 60-100%) * Life expectancy \> 3 months * Myeloid engraftment with absolute neutrophil count \> 1,000/μL and platelet count \> 50,000/μL (after allogeneic hematopoietic stem cell transplantation \[AHSCT\]) * Total bilirubin normal * AST and ALT ≤ 2.5 times upper limit of normal (ULN) * AST \< 3 times ULN after AHSCT * Creatinine clearance ≥ 50 mL/min in stratum 1 or ≥ 30 mL/min in stratum 2 * DLCO \> 40% with no symptomatic pulmonary disease * LVEF ≥ 30% by echocardiogram or MUGA * Not pregnant or nursing * Negative pregnancy test * Fertile patients must agree to use two acceptable methods of contraception (one highly effective method and one additional effective method) or practice abstinence for ≥ 28 days before, during, and ≥ 28 days after completing lenalidomide * HIV negative * No uncontrolled infection requiring intravenous therapy or poorly controlled diabetes mellitus * No history of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide * No uncontrolled intercurrent illness including, but not limited to, any of the following: * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Psychiatric illness and/or social situations that would limit compliance with study requirements * No history of grade 3 or 4 graft-vs-host disease (GVHD) * If patient has acute GVHD grade 1 or 2, GVHD must be controlled and dose of oral prednisone or equivalent ≤ 20 mg per day (after AHSCT) * More than 4 weeks since prior chemotherapy (excluding steroids), radiotherapy, or radioimmunoconjugate therapy (6 weeks for nitrosoureas or mitomycin C) and recovered * No other concurrent investigational agents